Daniel Aaron Pollyea
Impact in
- Hematology top 0.02%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Glioma Diagnosis and Treatment
Papers in
- Hematology 192
- Acute Myeloid Leukemia Research 173
- Hematopoietic Stem Cell Transplantation 12
- Chronic Myeloid Leukemia Treatments 6
- Genetics 6
- Myeloproliferative Neoplasms: Diagnosis and Treatment 4
- Chronic Lymphocytic Leukemia Research 2
- Co-authors
- Craig T. Jordan (45 shared papers)Courtney Denton Dinardo (29 shared papers)Brian Andrew Jonas (13 shared papers)Marina Y Konopleva (11 shared papers)Andrew H. Wei (9 shared papers)Clayton A. Smith (30 shared papers)Jalaja Potluri (16 shared papers)Hagop M. Kantarjian (11 shared papers)
- Journals
- Blood (52 papers)American Journal of Hematology (16 papers)Haematologica (13 papers)Journal of the National Comprehensive Cancer Network (9 papers)Blood Advances (9 papers)
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Daniel Aaron Pollyea
224 papers receiving 19.6k citations
Daniel Aaron Pollyea's Hit Papers
Peers
Comparison fields: 5 of 96
- Hematology 12.6k
- Genetics 610
- Cancer Research 578
- Molecular Biology 1.6k
- Oncology 547
Countries citing papers authored by Daniel Aaron Pollyea
This map shows the geographic impact of Daniel Aaron Pollyea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Aaron Pollyea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Aaron Pollyea more than expected).
Fields of papers citing papers by Daniel Aaron Pollyea
This network shows the impact of papers produced by Daniel Aaron Pollyea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Aaron Pollyea. The network helps show where Daniel Aaron Pollyea may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Aaron Pollyea, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 236 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Hit paper breakdown → | 2018 | 1448 |
| 2 | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Hit paper breakdown → | 2017 | 1224 |
| 3 | Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML Hit paper breakdown → | 2018 | 1182 |
| 4 | Functional genomic landscape of acute myeloid leukaemia Hit paper breakdown → | 2018 | 1011 |
| 5 | Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia Hit paper breakdown → | 2016 | 910 |
| 6 | Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study Hit paper breakdown → | 2018 | 613 |
| 7 | Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia Hit paper breakdown → | 2018 | 591 |
| 8 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2017 | 570 |
| 9 | Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells Hit paper breakdown → | 2018 | 488 |
| 10 | OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML Hit paper breakdown → | 2013 | 454 |
| 11 | 2015 | 416 | |
| 12 | Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia Hit paper breakdown → | 2020 | 408 |
| 13 | Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome Hit paper breakdown → | 2018 | 400 |
| 14 | Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2019 | 351 |
| 15 | 2015 | 339 | |
| 16 | Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia Hit paper breakdown → | 2019 | 311 |
| 17 | 2016 | 290 | |
| 18 | 2018 | 273 | |
| 19 | Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia Hit paper breakdown → | 2022 | 253 |
| 20 | 2016 | 248 |
About Daniel Aaron Pollyea
Daniel Aaron Pollyea is a scholar working on Hematology, Genetics, Oncology, Cancer Research and Molecular Biology, having authored 236 papers that have together received 19.8k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (173 papers), Hematopoietic Stem Cell Transplantation (12 papers), Chronic Myeloid Leukemia Treatments (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers), CAR-T cell therapy research (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), Cytomegalovirus and herpesvirus research (2 papers) and Global Cancer Incidence and Screening (2 papers). The work is most often cited by research in Hematology (12.6k citations), Genetics (610 citations), Cancer Research (578 citations), Molecular Biology (1.6k citations) and Oncology (547 citations). Daniel Aaron Pollyea has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Craig T. Jordan, Courtney Denton Dinardo, Brian Andrew Jonas, Marina Y Konopleva, Andrew H. Wei, Clayton A. Smith, Jalaja Potluri, Hagop M. Kantarjian, Brett M. Stevens and Brenda Chyla. Their work appears in journals such as Blood, American Journal of Hematology, Haematologica, Journal of the National Comprehensive Cancer Network and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.